These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 12838524)

  • 21. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
    Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
    Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors.
    Antonini A; Schwarz J; Oertel WH; Beer HF; Madeja UD; Leenders KL
    Neurology; 1994 Jul; 44(7):1325-9. PubMed ID: 8035939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.
    Kumakura Y; Danielsen EH; Reilhac A; Gjedde A; Cumming P
    Acta Neurol Scand; 2004 Sep; 110(3):188-95. PubMed ID: 15285777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
    Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
    Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
    N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study.
    Nurmi E; Bergman J; Eskola O; Solin O; Hinkka SM; Sonninen P; Rinne JO
    J Cereb Blood Flow Metab; 2000 Nov; 20(11):1604-9. PubMed ID: 11083235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.
    Pöpperl G; Tatsch K; Ruzicka E; Storch A; Gasser T; Schwarz J
    J Neural Transm (Vienna); 2004 Aug; 111(8):1041-52. PubMed ID: 15254792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seasonality of striatal dopamine synthesis capacity in Parkinson's disease.
    Kaasinen V; Jokinen P; Joutsa J; Eskola O; Rinne JO
    Neurosci Lett; 2012 Nov; 530(1):80-4. PubMed ID: 23041046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease.
    Taylor AC; Beerahee A; Citerone DR; Cyronak MJ; Leigh TJ; Fitzpatrick KL; Lopez-Gil A; Vakil SD; Burns E; Lennox G
    Pharmacotherapy; 1999 Feb; 19(2):150-6. PubMed ID: 10030765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine agonist monotherapy in Parkinson's disease.
    Clarke CE; Guttman M
    Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson's disease.
    Laihinen AO; Rinne JO; Någren KA; Lehikoinen PK; Oikonen VJ; Ruotsalainen UH; Ruottinen HM; Rinne UK
    J Nucl Med; 1995 Jul; 36(7):1263-7. PubMed ID: 7790953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What has PET told us about Parkinson's disease?
    Aquilonius SM
    Acta Neurol Scand Suppl; 1991; 136():37-9. PubMed ID: 1801535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia.
    Turjanski N; Bhatia K; Burn DJ; Sawle GV; Marsden CD; Brooks DJ
    Neurology; 1993 Aug; 43(8):1563-8. PubMed ID: 8351012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: a positron emission tomographic study.
    Brooks DJ; Ibanez V; Playford ED; Sawle GV; Leigh PN; Kocen RS; Harding AE; Marsden CD
    Ann Neurol; 1991 Aug; 30(2):166-71. PubMed ID: 1897909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.
    Torstenson R; Hartvig P; Långström B; Westerberg G; Tedroff J
    Ann Neurol; 1997 Mar; 41(3):334-40. PubMed ID: 9066354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.